11:30 AM EDT, 08/27/2025 (MT Newswires) -- Eli Lilly's ( LLY ) late-stage study of orforglipron for treating obesity and type 2 diabetes showed a "clear positive," with efficacy on par with Novo Nordisk's ( NVO ) Wegovy in the same population, UBS Securities said Tuesday in a report.

Orforglipron has a "solid" clinical profile in obesity and offers a more "optimistic" commercial outlook than expected by Wall Street. UBS said.

Investors await more data on overall dropout rates, weight loss kinetics in the obesity population excluding type 2 diabetes, gastrointestinal side effects and physician feedback, the report said.

UBS maintained Eli Lilly's ( LLY ) stock rating at buy with an $895 price target.

Eli Lilly ( LLY ) shares gained 0.2% in Wednesday trading, and Novo Nordisk ( NVO ) rose 0.1%.

Price: 738.09, Change: +2.06, Percent Change: +0.28